CEO
Basecamp Research
Basecamp Research is a frontier AI company developing AI-designed medicines by training EDEN foundation models on BaseData, the world's largest proprietary evolutionary genomic dataset with over 100 billion novel genes. The company's models generate therapeutic candidates directly from disease information, spanning gene insertion, gene editing, and peptide design, with an initial focus on in vivo cell therapy.
- Drug Discovery & Therapeutics
- Artificial Intelligence
- Biotechnology
- Healthcare Technology
- Agriculture Technology
- Data & Analytics
- Enterprise Software
Updated 1 month ago
Funding
Raised to date
$225MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$200M across 2 disclosed rounds
+12$140M · Series C
Announced Sep 2026 · from article date
Disclosed cumulative: $200M
2/2
Reported total $225M
Incomplete round history. $25M of the $225M reported total isn’t matched to a known round.
RoundDateAmountValuationInvestors
Founders
Product
Problem
Developing new therapies for complex diseases is constrained by limited understanding of biological diversity, as most AI models are trained on narrow, publicly available genomic data that fails to capture the full evolutionary landscape. This restricts the ability to design effective medicines for conditions like cancer and autoimmune disease, where current cell therapies are limited in complexity and cost hundreds of thousands of dollars per patient.
Solution
Basecamp Research combines frontier AI models with the world's largest proprietary evolutionary genomic dataset, called BaseData, to design therapeutic candidates directly from disease information. The company's EDEN models are trained on over 100 billion novel genes collected through access and benefit-sharing partnerships across more than 30 countries and all seven continents, enabling recognition of patterns across previously unseen biology. Unlike single-task AI systems, EDEN models aim for universal understanding of DNA function across all life, generating candidates for cell and gene therapies, enzymes, and peptides. The company has demonstrated strong preclinical results across multiple modalities and disease areas, with its technology platform built in collaboration with partners including NVIDIA, Anthropic, PacBio, and Ultima Genomics.
Target Audience
Basecamp Research serves pharmaceutical and biotechnology companies seeking AI-designed therapeutic candidates, as well as research institutions and partners interested in advancing cell and gene therapy programs through frontier AI models.
Features
- EDEN foundation models trained on BaseData, the largest proprietary evolutionary genomic dataset with over 100 billion novel genes and 100T+ tokens of biological data
- Universal DNA understanding across all life forms, enabling generation of therapeutic candidates directly from disease information
- Capabilities spanning gene insertion, gene editing, and peptide design for multiple therapeutic modalities
- Technology built with partners including NVIDIA, Anthropic, PacBio, and Ultima Genomics for model training and data collection
- Preclinical validation across multiple disease areas including cancer and autoimmune disease
- Access and benefit-sharing partnerships in more than 30 countries across all seven continents for biodiversity data collection